We can do so in many ways. The first would involve support for translational research in Canada. That's something that is simply not subsidized here.
We subsidize the part of it that is related to biomanufacturing, and preclinical to clinical work. That enabled us to be remarkably successful. However, you need to be really capable of taking the results—our discoveries—from our laboratories and convert them into products that can be tested on, and potentially cure, human beings. It's essential.
We have to do that in Canada before even beginning discussions with our American and European colleagues, and those in Great Britain in particular. To have a large-scale mission, you really need to be able to treat all forms of cancer and make them curable. That's our organization's vision.